CROOKE STANLEY T 4
4 · IONIS PHARMACEUTICALS INC · Filed Nov 30, 2020
Insider Transaction Report
Form 4
CROOKE STANLEY T
DirectorChairman, President, CEO
Transactions
- Sale
Common Stock
2020-11-25$50.05/sh−12,990$650,150→ 2,021 total - Exercise/Conversion
Common Stock
2020-11-25$39.87/sh+12,990$517,911→ 15,011 total - Exercise/Conversion
Non-Qualified Stock Option (right to buy)
2020-11-25−12,990→ 0 totalExercise: $39.87From: 2015-01-02Exp: 2021-01-01→ Common Stock (0 underlying)
Holdings
- 1,581(indirect: By Spouse)
Common Stock
- 650,391(indirect: By Trust)
Common Stock
Footnotes (3)
- [F1]Acquired as a result of exercising a stock option that was scheduled to expire on 1/1/21. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2019.
- [F2]Shares sold pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person on March 13, 2019.
- [F3]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.85 to $50.25, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) of this Form 4.